Please find attached letter on your record.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emrock Corporation has filed a formal statement confirming a deviation in the use of proceeds from its earlier preferential issue of 1.06 crore convertible warrants (at Rs. 11 each, face value Rs. 10). During the quarter ended December 31, 2025, all 1.06 crore warrants were exercised into equity shares, bringing in Rs. 8.74 crore as the warrant exercise amount. Cumulative proceeds received so far stand at around Rs. 15.22 crore, with about Rs. 10.67 crore still expected within 18 months. The deviation arises because the company altered its main objects clause — originally funds were meant for working capital and general corporate purposes, but three new objects (Renewable Energy, Pharma, and Hospitality) were added alongside Infrastructure, with shareholder approval received on October 11, 2025. The Audit Committee noted that despite the object change, funds were still used only towards the main objects. No monetary deviation was reported for the quarter.
This is a routine but important compliance disclosure under SEBI rules. Shareholders had already approved the expanded business scope, so there's no governance red flag, but the new verticals (renewable energy, pharma, hospitality) signal a major diversification push. Investors should watch for further clarity on how the remaining Rs. 10.67 crore will be deployed across these new business areas.